Finland-based startup Combinostics raises $4.3M to support early Alzheimer’s diagnosis by healthcare professionals
There are no effective treatments for neurodegenerative diseases like Alzheimer’s, but early-stage diagnosis combined with symptomatic treatment and lifestyle intervention can make a drastic difference to quality of life in later years. A vast amount of heterogeneous data is collected during the diagnostic workup, so it can be challenging for healthcare professionals to interpret and identify relationships that exist between different data sets. Enter Combinostics, a Tampere, Finland-based healthtech startup that provides an intuitive and holistic view of the patient’s data, highlighting important relationships early on and supporting early diagnosis.
Today, Combinostics announced it has closed $4.3M (€3.9M) Series A funding round that will see the company scale its platform for early-stage Alzheimer’s diagnosis to the US and Asia. The round was jointly-led by Industrifonden and NordicNinja VC, with Combinostics representing NordicNinja’s fifth deep tech investment over the past 6 months.
Founded in 2014 in Tampere, Finland, Combinostics’ mission is to support healthcare professionals in the diagnosis and treatment of neurodegenerative diseases with the overall goal to improve patient quality of life in later years. Its cNeuro platform combines imaging data with clinical data and provides an intuitive and holistic view of patient data that highlights important relationships early on and supports early diagnosis. Its users include radiology and neurology departments in the EU, US, Japan, and South Korea.
“I would like to thank Industrifonden and NordicNinja for demonstrating their trust in Combinostics with this investment, as well as our previous early-stage angel investors,” said Combinostics CEO Lennart Thurfjell. “Industrifonden has a proven track record for supporting companies throughout their journeys, and NordicNinja has strong ties with Asia – Japan in particular – a very important target market for our technology. We will use this investment to ramp up R&D, build our US operations, and expand in Asia. We currently have a partner working on regulatory approval in Japan, and we are looking for a partner in China.”
“Our investment in Combinostics represents another step for our long-term commitment to health tech innovation. The company joins a family of startups that are improving health outcomes globally by building category-leading products,” said Industrifonden Investment Manager Patrik Sobocki.
“Combinostics has built a product platform from cutting-edge research that will enhance neurology departments worldwide,” he continued. “Their platform supports improved diagnostic accuracy and treatment choice by combining all relevant biomarkers with advanced brain image quantification, leading to improved health in neurology patients.”